XtalPi pitches software stack to speed drug discovery

By AI, Created 5:22 AM UTC, May 29, 2026, /AGP/ – XtalPi is highlighting a software-and-robotics platform it says can cut the time and cost of early drug discovery by linking quantum physics, AI and lab validation. The company is also pointing to new products, its Hong Kong listing and a global R&D footprint as it expands beyond pharmaceuticals.

Why it matters: - XtalPi is positioning intelligent software as a way to replace slow, manual drug development workflows with data-driven and automated systems. - The company says the approach can help researchers move through chemical space faster and reduce the cost of bringing new therapies to market. - XtalPi is using the same platform across pharmaceuticals, new materials, renewable energy and environmental management.

What happened: - XtalPi outlined a unified platform that combines quantum physics, artificial intelligence and large-scale robotics. - The company was founded in 2015 by three MIT-trained physicists. - XtalPi listed on the Hong Kong Stock Exchange in June 2024 under HKEX:2228. - The listing made XtalPi the first specialized technology company listed under Chapter 18C. - More than 70% of XtalPi’s workforce focuses on research and development. - XtalPi operates across Shenzhen, Shanghai, Beijing, Boston and Liverpool. - The company runs more than 10,000 square meters of wet laboratory space.

The details: - PatSight uses computer vision and natural language processing to identify and digitize chemical structures from patent literature, internal reports and academic journals. - PatSight makes the resulting chemical intelligence searchable for computational modeling. - PatSight also aggregates experimental results from public databases and proprietary wet-lab outputs to map bioactivity data. - The platform normalizes potency, selectivity and safety data to help teams rank candidate molecules. - MolValley serves as a centralized digital workbench for molecular data. - MolValley includes sub-structure and similarity search tools for internal libraries. - The platform is designed to give project teams a single source of truth for molecules synthesized or tested. - MolValley adds SAR analysis and AI-driven ADMET profiling to flag developability risks such as metabolic stability and cardiotoxicity. - XMolGen is designed as an intelligent co-pilot for molecular design. - XMolGen supports R-group replacement, scaffold hopping and de novo design in one interface. - The system combines generative AI with chemical rules. - XMolGen checks generated molecules against internal retrosynthetic logic and commercial building-block databases to improve synthetic feasibility. - XFEP is XtalPi’s Free Energy Perturbation platform for binding affinity prediction. - XtalPi says XFEP raises FEP throughput by 10 to 100 times versus conventional commercial software. - XFEP can evaluate more than 1,000 molecules per day. - XtalPi says XFEP has been validated across dozens of internal drug discovery pipelines. - The company says XFEP’s predictions align with wet-lab results and includes automated setup and real-time correlation analysis. - XtalPi says its technical core relies on more than 200 proprietary AI models trained on quantum physics calculations and verified wet-lab data. - The company describes its setup as a wet-lab and dry-lab integration.

Between the lines: - XtalPi is making a broader case that drug discovery should be treated as an engineering problem, not just a trial-and-error scientific process. - The software stack appears designed to connect data capture, molecular design, prediction and lab validation inside one workflow. - The company’s pitch centers on scale: faster data extraction, faster modeling and faster experimental feedback. - The emphasis on synthetic accessibility suggests XtalPi wants to avoid generating molecules that cannot be made in a lab.

What’s next: - XtalPi is likely to keep pushing its platform as a commercial tool for pharma partners and adjacent industries. - The company’s website provides more information at the official website. - XtalPi can also be reached at +1 617-487-3080.

The bottom line: - XtalPi is betting that tightly linking AI, physics and robotics can make drug discovery faster, more scalable and less dependent on manual effort.